Evidence map›Paper›PMID 27800660›Full record

Trial reportStem cells (Dayton, Ohio)2017

Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells.

Charles S Cox, Robert A Hetz, George P Liao, Benjamin M Aertker, Linda Ewing-Cobbs, Jenifer Juranek, Sean I Savitz, Margaret L Jackson, Anna M Romanowska-Pawliczek, Fabio Triolo and 8 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cells (Dayton, Ohio), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163833 (MATRIx), which is not on this map. Cited by 75 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 3 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06163833 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury

TypeinterventionalSponsorFondazione IRCCS San Gerardo dei TintoriRan2023 to 2026Enrolled78ConditionsTraumatic Brain Injury With Loss of ConsciousnessArmsMesenchymal stromal cell low dosage-80*10^6 cells, Mesenchymal stromal cell low dosage-160*10^6 cells, Placebo-storage solution
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Bidirectional Interaction Between the Brain and Bone in Traumatic Brain Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Charles S CoxDepartment of Pediatric Surgery, The University of Texas McGovern Medical School, Houston, Texas, USA.
Robert A HetzDepartment of Surgery, The University of Texas McGovern Medical School, Houston, Texas, USA.
George P LiaoDepartment of Surgery, The University of Texas McGovern Medical School, Houston, Texas, USA.
Benjamin M AertkerDepartment of Neurology, The University of Texas McGovern Medical School, Houston, Texas, USA.
Linda Ewing-CobbsDepartment of Pediatrics, The University of Texas McGovern Medical School, Houston, Texas, USA.
Jenifer JuranekDepartment of Pediatrics, The University of Texas McGovern Medical School, Houston, Texas, USA.
Sean I SavitzDepartment of Neurology, The University of Texas McGovern Medical School, Houston, Texas, USA.
Margaret L JacksonDepartment of Pediatric Surgery, The University of Texas McGovern Medical School, Houston, Texas, USA.
Anna M Romanowska-PawliczekDepartment of Pediatrics, The University of Texas McGovern Medical School, Houston, Texas, USA.
Fabio TrioloDepartment of Pediatric Surgery, The University of Texas McGovern Medical School, Houston, Texas, USA.
Pramod K DashDepartment of Neurobiology and Anatomy, The University of Texas McGovern Medical School, Houston, Texas, USA.
Claudia PedrozaCenter for Clinical Research and Evidence-Based Medicine, The University of Texas McGovern Medical School, Houston, Texas, USA.
Dean A LeeDepartment of Hematology and Oncology, Nationwide Children's, Columbus, Ohio, USA.
Laura WorthDepartment of Pediatrics, MD Anderson Cancer Center, Houston, Texas, USA.
Imoigele P AisikuDepartment of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Huimahn A ChoiDepartment of Neurology, The University of Texas McGovern Medical School, Houston, Texas, USA.
John B HolcombDepartment of Surgery, The University of Texas McGovern Medical School, Houston, Texas, USA.
Ryan S KitagawaDepartment of Neurosurgery, The University of Texas McGovern Medical School, Houston, Texas, USA.
The University of Texas Health Science Center · USThe University of Texas Health Science Center at Houston · USBrigham and Women's Hospital · USNationwide Children's Hospital · USThe University of Texas MD Anderson Cancer Center · US

Funding

Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
ROLE OF THE GUT IN POST INJURY MULTIPLE ORGAN FAILURET32GM008792 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Charles S Cox · 2001 to 2026
$5.2M
NCATS NIH HHS UL1 TR000371NIGMS NIH HHS T32 GM008792
6 · The paper itself

Abstract

Preclinical studies using bone marrow derived cells to treat traumatic brain injury have demonstrated efficacy in terms of blood-brain barrier preservation, neurogenesis, and functional outcomes. Phase 1 clinical trials using bone marrow mononuclear cells infused intravenously in children with severe traumatic brain injury demonstrated safety and potentially a central nervous system structural preservation treatment effect. This study sought to confirm the safety, logistic feasibility, and potential treatment effect size of structural preservation/inflammatory biomarker mitigation in adults to guide Phase 2 clinical trial design. Adults with severe traumatic brain injury (Glasgow Coma Scale 5-8) and without signs of irreversible brain injury were evaluated for entry into the trial. A dose escalation format was performed in 25 patients: 5 controls, followed 5 patients in each dosing cohort (6, 9, 12 ×10

Indexed as

AdultBehaviorBiomarkersBone Marrow CellsBrain Injuries, TraumaticCorpus CallosumCytokinesFemaleGray MatterHumansInflammation MediatorsLeukocytes, MononuclearMalePyramidal TractsTreatment OutcomeBiomarkersCytokinesInflammation Mediatorsadult human bone marrowadult stem cellsbone marrow stromal cellscellular therapyclinical trialsdiffusion tensor imagingtraumatic brain injury

Identifiers

PMID27800660
PMCPMC5367945
OpenAlexW2548344299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.